ProCE Banner Activity


Advances in the Treatment of T-Cell Lymphomas: A Forum for Data and Case Discussion


Watch this on-demand webcast from an ASH satellite symposium on applying recent clinical findings in T-cell lymphomas, including discussions on individualizing treatment, newer targeted agents, toxicity management, and clinical trials.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: January 31, 2023

Expiration: January 30, 2024



Steven M. Horwitz

Steven M. Horwitz, MD

Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Memorial Hospital
Professor of Medicine, Weill Cornell Medical College
New York, New York

Pamela B. Allen

Pamela B. Allen, MD, MSc

Assistant Professor
Department of Hematology/Oncology
Emory University, Winship Cancer Institute
The Emory Clinic
Atlanta, Georgia

Kerry Savage

Kerry Savage, MD, MSc

Associate Professor
Department of Medicine, Division of Medical Oncology
Medical Oncologist
Department of Medical Oncology
British Columbia Cancer Agency
Vancouver, British Columbia, Canada

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from

Daiichi Sankyo

Kyowa Kirin Inc

Seagen Inc.

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with T-cell lymphomas.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in selecting individualized treatments for patients with T-cell lymphomas.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment decisions in patients with T-cell lymphomas based on assessment of molecular and phenotypic biomarkers and accurate lymphoma subclassification

  • Integrate single-agent or combination targeted therapy into management plans for patients with T-cell lymphomas

  • Evaluate the latest clinical trial data for novel agents and emerging therapeutic strategies across different T-cell lymphomas

  • Manage treatment-related adverse events through agent familiarity and robust monitoring efforts 

  • Identify patients diagnosed with T-cell lymphomas who are eligible for enrollment on ongoing clinical trials


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Steven M. Horwitz, MD: consultant/advisor/speaker: Acrotech, C4 Therapeutics, Cimeio Therapeutics, Myeloid Therapeutics, Seattle Genetics, Shoreline Biosciences, Takeda, Tubulis, Vividion Therapeutics.

Pamela B. Allen, MD, MSc: consultant/advisor/speaker: ADC Therapeutics, Daiichi Sankyo, Epizyme, Kyowa Kirin, Secura Bio.

Kerry Savage, MD, MSc: consultant/advisor/speaker: AbbVie, Bristol-Myers Squibb, Janssen, Merck, Novartis, Seagen; researcher: Bristol-Myers Squibb; steering committee: BeiGene; data and safety monitoring committee: Regeneron.

Planner/Manager Text

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 31, 2023, through January 30, 2024:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.